Rabeprazole for the prevention of pathologic and symptomatic relapse of erosive or ulcerative gastroesophageal reflux disease

American Journal of Gastroenterology

Volumn 95, Issue 11, 2000, Pages 3081-3088

  Caos, Antonio ^a   Moskovitz, Morry ^b   Dayal, Yogeshwar ^c   Perdomo, Carlos ^d   Niecestro, Robert ^d   Barth, Jay ^d  

^a Central Florida Clinical Studies   (United States)

^b Valley Gastroenterology Associates   (United States)

^c TUFTS MEDICAL CENTER   (United States)

^d EISAI INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; GASTRIN; PLACEBO; RABEPRAZOLE;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CLASSIFICATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENDOSCOPY; FEMALE; GASTRIN BLOOD LEVEL; GASTROESOPHAGEAL REFLUX; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; STOMACH CHIEF CELL; STOMACH PARIETAL CELL;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ANTI-ULCER AGENTS; BENZIMIDAZOLES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ESOPHAGITIS, PEPTIC; FEMALE; FOLLOW-UP STUDIES; GASTROESOPHAGEAL REFLUX; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; PROTON PUMPS; PROTON-TRANSLOCATING ATPASES; RECURRENCE; SAFETY; TIME FACTORS;

EID: 0033756119     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(00)01972-9     Document Type: Article

References (23)

1. The prevalence of gastro-oesophageal reflux disease
2. Prevalence and clinical spectrum of gastroesophageal reflux: A population-based study in Olmsted County, Minnesota
3. Epidemiology of reflux disease and reflux esophagitis
4. Healing and relapse of severe peptic esophagitis after treatment with omeprazole
5. Medical treatment of reflux esophagitis
6. +, -ATPase is correlated with the rate of acid-activation of the inhibitor
7. +, -ATPase is inhibited by E3810 (2-[{4-(3-methoxypropoxy)-3-methylpyridin-2-y1}-methylsulfinyl]-1H-benzimid azole, sodium)
8. The secretion of acid from isolated rabbit gastric glands is inhibited by E3810 (2- [{4-(3-methoxypropoxy)-3-methylpyridin-2-y1}-methylsulfinyl]-1H-benzimidazo le, sodium)
9. Histamine-stimulated gastric acid secretion is inhibited in gastric fistula dogs treated with E3810 (2-[{4-(3-methoxypropoxy)-3-methylpyridin-2-yl)-methylsulfinyl]-1H-benzimida zole, sodium)
10. Rabeprazole
11. Rabeprazole in treatment of acid peptic diseases: Results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD)
12. Rabeprazole sodium (E3810) once daily is superior to ranitidine 150 mg QID in the healing of erosive or ulcerative gastroesophageal reflux disease
13. Double-blind, placebo-controlled comparison of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease
14. Recognition and the histopathologic classification of ECL cell proliferations
15. Histopathological classification of nonantral gastric endocrine growths in man
16. Omeprazole: An updated review of its pharmacology and therapeutic use in acid-related disorders
17. Lansoprazole: An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders
18. Rabeprazole for the prevention of recurrent erosive or ulcerative gastroesophageal reflux disease
19. Lansoprazole versus ranitidine in the maintenance treatment of reflux oesophagitis
20. Long-term acid control and proton pump inhibitors: Interactions and safety issues in perspective
21. Argyrophil ECL histology in the gastric corpus and antrum in 243 patients taking rabeprazole 10 mg or 20 mg or omeprazole 20 mg for one year
22. Rabeprazole does not affect endocrine function in healthy subjects
23. In vivo and in vitro studies of the site of inhibitory action of omeprazole on adrenocortical steroidogenesis